Concord Biotech Board to Consider Q2 and H1 Results on 27th Oct'26
Concord Biotech Ltd 路 Intimation 路 27 Oct 2026, 5:30 am
Concord Biotech Board to Consider Q2 and H1 Results on 27th Oct'26 Concord Biotech Ltd announced that its Board of Directors will meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26, alongside the Limited Review Report from Statutory Auditors. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and their immediate relatives until 48 hours post the declaration of the financial results.
Original exchange filing (PDF)
More announcements from Concord Biotech Ltd
- Intimation of allotment of Bonus equity Shares 路 05 Nov 2026
- Transcript of Q2 - FY27 Earnings call held on October 28, 2026 路 03 Nov 2026
- Earning Call Recording- For the Second Quarter and half year ended on September 30, 2026 路 29 Oct 2026
- Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026. 路 28 Oct 2026
- Investor''s presentation on unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026 路 28 Oct 2026
- The Board of Directors at its meeting held on October 27, 2026 has fixed Wednesday, November 04, 2026 as record date for issuance of Bonus equity shares in the ratio of 1:1. 路 28 Oct 2026
- Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026. 路 28 Oct 2026
- Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 28 Oct 2026
